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ABSTRACT 
  Progesterone receptor membrane component 1 (PGRMC1), PGRMC2, neudesin, and neuferricin 
all contain a cytochrome b5-like heme/steroid-binding domain and belong to the 
membrane-associated progesterone receptor (MAPR) family. Their amino acid sequences are well 
conserved among vertebrates, from humans to zebrafish. MAPR family genes are abundantly 
expressed in the central nervous system and exhibit neurotrophic effects in neural cells. During lipid 
metabolism, PGRMC1 regulates cholesterol synthesis, and neudesin plays a role in adipogenesis. 
Their bioactivities are dependent on the binding of heme to their cytochrome b5-like 
heme/steroid-binding domains. Conversely, it has been reported that the binding of steroids to 
MAPR family proteins induces biological responses that are unrelated to the nuclear steroid 
receptors. The interaction between PGRMC1 and progesterone promotes cell survival and damage 
resistance by progesterone. Moreover, MAPR family proteins exhibit a unique expression pattern in 
breast cancer, indicating the possibility of using MAPR family members as drug target in breast 
cancer. In this review, we summarize the identification, structure, and bioactivity of members of the 
MAPR family, and present an essential overview of the current understanding of their physiological 
roles. 
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We recently identified two novel extracellular heme-binding proteins and named them neudesin 
and neuferricin [1, 2]. Both belong to the membrane-associated progesterone receptor (MAPR) 
family, a subfamily of the cytochrome b5 (cyt-b5) family, which consists of heme-binding proteins 
with cyt-b5-like heme/steroid-binding domains [3]. Progesterone receptor membrane component 1 
(PGRMC1) and the closely related PGRMC2 are also as members of the MAPR family in mammals 
[4, 5]. Members of the MAPR family have a highly homologous primary structure (Table 1), but 
have distinct localization patterns, that is, neudesin and neuferricin are both secreted proteins, while 
PGRMC1 and PGRMC2 are single transmembrane proteins. All of them possess a heme-binding 
domain, and their bioactivities are dependent on the binding of heme to their cyt-b5-like 
heme/steroid-binding domains. Several heme-binding proteins have been isolated and characterized 
recently [6-9]. Heme is a key component of many biochemical reactions. Heme serves as a 
prosthetic group in the heme-binding proteins, such as the hemoglobins, cytochromes, and guanylate 
cyclases. It has important transportation, catalytic, electron transfer, and signaling functions. 
Heme-binding proteins are also involved in many important cellular functions. For example, 
hemoglobin and myoglobin are among the most abundant heme-binding proteins associated with 
oxygen transportation [6]. while the cytochromes are involved in electron transport and 
steroidogenesis [7], and the guanylate cyclases catalyze the conversion of GTP to cGMP [8]. In 
addition, it has been reported that the binding of heme to DGCR8, another heme-binding protein, is 
related to microRNA processing [9]. Thus, heme-binding proteins may play important roles in 
biological functions, and some unidentified heme-binding proteins that have novel functions may 
exist. Here, we provide an overview of the structure and function of this unique heme-binding 
protein family. 
 
 1. PGRMC1 (sigma-2 receptor, Hpr6.6, 25-Dx)  
1.1. Structure and binding studies 
  PGRMC1 is a member of a multi-protein progesterone-binding complex that co-purifies with 
progesterone-binding proteins in the liver and ovary [10, 11]. PGRMC1 is a 26-28 kDa vertebrate 
protein with a single transmembrane domain. The protein has been identified from porcine liver 
firstly as putative membrane receptor of progesterone [10]. Subsequently, homologous proteins were 
cloned in rats (25-Dx), mice (PGRMC1) and humans (Hpr.6) [12]. However, PGRMC1 does not 
bind directly to progesterone [13] and shares no homology with the nuclear or other 
membrane-associated steroid receptors [3]. The only currently known biochemical function of 
PGRMC1 is that it binds to heme [14, 15]. It also shares key structural motifs with cyt-b5 [3]; the 
134-amino acid human cyt-b5 molecule posses a heme-binding domain in which His44 and His68 
act as the ligands for the heme iron [16]. The 195-amino acid human PGRMC1 possesses a 
heme-binding domain in which Tyr107 and Tyr113 act as the expected binding sites for the heme 
iron [13] (Fig. 1). On the other hand, PGRMC1 complex binds progesterone with a similar affinity 
as other steroids such as corticosterone, testosterone and cortisol [10], which suggests limited 
hormone-binding specificity. Curiously, progesterone binding to PGRMC1 complex can be 
competed with haloperidol, an anti-psychotic drug, with a Ki of 20 nM [10]. Progesterone binding is 
also inhibited by fluphenazine, carbetapentane citrate and R(-)-N-(3-phenyl-1-propyl)-1-phenyl-2 
aminopropane HCl (PPAP HCl) [10]. These suggests that the PGRMC1 complex is a mixed-function 
steroid/drug-binding complex (S/D-BP). In addition, PGRMC1 contains phosphorylation sites at 
serine-56, tyrosine-138, tyrosine-179, and serine-180 [17] (Fig. 1). Recently, PGRMC1 was 
identified as the sigma-2 receptor, a putative type of opioid receptor; sigma-2 receptors are reported 
to be induced in cancers [18, 19]. 
 
1.2. Expression 
PGRMC1 is highly expressed in the liver and kidney in humans, with lower expression observed in 
the brain, lung, heart, skeletal muscle, and pancreas [12]. In rodents, PGRMC1 is present in the liver, 
lung, kidney and brain [20, 21]. PGRMC1 is overexpressed in breast tumors and in cancer cell lines 
from the colon, thyroid, ovary, lung, and cervix [22]. In ovarian cancer, PGRMC1 expression has 
been found to increase in advanced-stage tumors, where it is expressed homogeneously throughout 
the tumor [23]. Microarray analyses have identified PGRMC1 expression in colon, lung and breast 
tumors [24-26]. The non-genotoxic carcinogen 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) induces 
PGRMC1 expression in the rat liver [21], but the induction is found only in males [27]. PGRMC1 is 
expressed in the ovary and corpus luteum, where expression is induced by progesterone [28] and 
during pregnancy [29], respectively. PGRMC1 is expressed in the various areas of the brain that are 
involved in CSF production (choroid plexus) [30], osmoregulation (hypothalamus, circumventricular 
organs, meninges) [30], and female reproductive behavior lordosis (ventromedial hypothalamus) 
[20]. PGRMC1 is expressed at a basal level in the rat cerebellum at birth; the mRNA and protein 
levels of PGRMC1 increased neonatally and decrease thereafter without a significant gender 
difference [31]. PGRMC1 is expressed primarily in Purkinje and external granule cells in the 
cerebellum of neonate rats, while it is expressed in Purkinje cells only in the adult cerebellum [31]. 
Cerebellar Purkinje cells are the sites of de novo synthesis of progesterone from cholesterol, where 
the steroid may promote dendritic growth, synaptogenesis, and spinogenesis. 
 
1.3. Signal transduction 
PGRMC1 binds and activates the P450 proteins [13, 32, 33], which are involved in drug, hormone 
and lipid metabolism. It also interacts with insulin-induced gene-1 (Insig-1) [34], which regulates 
synthesis of cholesterol [35]. In cancer cells, PGRMC1 promotes cell death after oxidative damage, 
possibly related to Akt and IB degradation but does not itself appear to act directly on Akt and IB 
molecules [36]. On the other hand, progesterone inhibits apoptosis in immortalized granulosa cells, 
which requires PGRMC1 and its binding partner plasminogen activator inhibitor RNA-binding 
protein-1 (PAIR-BP1) [11]. The component of PGRMC1 complex that binds to progesterone remains 
unknown because PGRMC1 and PAIR-BP1 do not directly interact with progesterone. 
 
1.4. Physiological functions 
The physiological roles of PGRMC1 have been reported so far in steroid synthesis and metabolism 
[37], cholesterol regulation [32, 38-40], axonal guidance [41], endocytosis, and alteration of 
reproductive behaviors [20]. It also acts together with progesterone as a component of a 
progesterone receptor, and plays roles in intracellular signal transduction and/or membrane 
trafficking as an adapter protein [42]. PGRMC1 is induced by progesterone after traumatic brain 
injury, effecting neuroprotective activities in a number of model systems of brain lesions [43, 44]. 
Additionally, pseudopregnant rats display higher PGRMC1 expression [30], which also corresponds 
with neuroprotection. However, it is unclear whether PGRMC1 regulates neuroprotection directly. 
Very recently, progesterone-PGRMC1 signaling has been reported to directly and rapidly suppress 
GnRH neuronal activity via inhibition of intracellular calcium oscillation in GnRH neuron [45]. The 
PGRMC1 yeast homologue, damage associated protein 1 (Dap1), binds heme [14, 38] through a 
penta-coordinate mechanism [14, 46]. Yeast cells lacking the DAP1 gene are sensitive to DNA 
damage [39], and heme binding is necessary for damage resistance [38]. Dap1 is also necessary for a 
crucial step in cholesterol synthesis, where the P450 protein Erg11/Cyp51 removes a methyl group 
from lanosterol [32, 38-40]. Erg11/Cyp51 is the target of the azole antifungal drugs. Accordingly, 
yeast cells without the DAP1 gene are highly sensitive to antifungal drugs [32, 38, 39]. Dap1 also 
regulates the metabolism of iron in yeast [40].  In yeast and humans, PGRMC1/DAP1 binds directly 
to P450 proteins, including CYP51A1, CYP3A4, CYP7A1 and CYP21A2 [32]. PGRMC1 also 
activates Cyp21 when the two proteins are co-expressed in COS-7 cells [13, 33], indicating that 
PGRMC1 promotes progesterone turnover. Just as Dap1 is required for the action of Erg11 in the 
synthesis of ergosterol in yeast, PGRMC1 regulates the Cyp51-catalyzed demethylation step in 
human cholesterol synthesis [32]. Therefore, PGRMC1 and its homologues bind and regulate P450 
proteins, and have been likened to “a helping hand for P450 proteins” [47]. The yeast PGRMC1 
homologue is required for resistance to damage [39]. PGRMC1 also promotes survival in human 
cancer cells after chemotherapy treatment [11, 15]. Conversely, it promotes cell death in cancer cells 
after oxidative damage [48]. Moreover, a recent study has shown that PGRMC1, as well as its 




PGRMC1 is up-regulated in many types of cancer.  PGRMC1 is part of a protein signature that 
predicts hypoxia in breast cancer [25], which is reminiscent of its induction during hypoxia in S. 
pombe [32]. In contrast, in ovarian cancer, PGRMC1 is inactivated by hypermethylation of the 
PGRMC1 promoter [50]. PGRMC1 is also implicated as a biomarker in other steps during cancer 
progression. Nie et al. identified a carcinogenicity signature in rats that included PGRMC1 and five 
genes in response to 52 known carcinogenic compounds [51]. Hokaiwado et al. performed a similar 
analysis and identified PGRMC1 [52]. PGRMC1 was originally cloned as 25-Dx in the rat liver 
because of TCDD-induced modification of gene expression [21]. TCDD also induces P450 proteins 
such as Cyp1A1 [53]. It is reported that P450 proteins like Cyp1A1 trigger tumor formation, a 
possible mechanism of which may be P450-mediated oxidative damage [54]. It is noteworthy that 
human PGRMC1/25-Dx promotes cell death in cancer cells after oxidative damage [48]. The effect 
of TCDD on PGRMC1/25-Dx expression is gender-specific, so that the expression is induced in 
male rats but repressed in females [27]. TCDD induces liver tumors in females but not in males [55], 
which suggests that the gender-specific expression patterns may contribute to the 
hepatocarcinogenicity of TCDD. PGRMC1/25-Dx expression is repressed by progesterone and 
estrogen in murine neurons [20]. It is possible that the steroids mediate the TCDD-induced reduction 
of PGRMC1/25-Dx expression in female rat livers. 
  Thus, as summarized in Table 2, the progesterone/heme-binding protein PGRMC1 is widely 
expressed in several tissues including the central nervous system and tumor lesions and cancer cells, 
and has a number of functions such as neuroprotection and cell survival. 
 
 
2. PGRMC2 (DG6)  
  PGRMC2 was first cloned by Gerdes et al. using the sequence of a porcine progesterone receptor 
as a probe, and designated DG6 [12]. Human PGRMC2 protein comprises 247 amino acids, with the 
transmembrane region and the cyt-b5 domain at its N- and C-terminus, respectively (Fig. 1). The 
cyt-b5 domain of PGRMC2 has 67% identity and 82% similarity to that of human PGRMC1. 
Northern blot analysis revealed PGRMC2 expression in all tissues examined, with highest 
expression in the placenta. Detailed analyses of the function of PGRMC2 have not been reported, 
but several studies suggest a possibility that PGRMC2, as well as PGRMC1, are involved in 
physiologically important activities. Recent reports show that PGRMC2 inhibits migration of 
SKOV-3 ovarian cancer cell, but has no effect on cell survival [56]. Moreover, Liu et al. reported 
that PGRMC1 and PGRMC2 were expressed in neural precursor cells and regulate cell proliferation 
through ERK activation [57]. In this report, analyses of PGRMC1 were performed, but not of 
PGRMC2, other than the expression profiles. Additionally, PGRMC2 was identified as one of the 
genes associated with ovarian reserve status in young women [58]. In this report, expression levels 
of PGRMC2 in membrana granulosa cells were validated in a group comprising normal and 
diminished ovarian reserve patients. PGRMC2 is also reported to be involved in advanced 
endometriosis [59]. The expression level of PGRMC2 was revealed to be markedly increased during 
the secretary phases of the endometrium, and PGRMC2 mRNA expression was dramatically 
decreased in endometriosis, exhibiting an alteration of intracellular staining patterns for the 
PGRMC2 protein when compared with disease-free animals.  
  As shown in Table 3, PGRMC2, which shows progesterone-binding and putative heme-binding 
properties, is widely expressed in several tissues including the placenta, and some cell types, 
including neural cells and cancer cells, and inhibits cell migration. However, Further analyses are 
needed to elucidate the detailed biological functions of PGRMC2.  
 
 
3. Neudesin (NENF)   
3.1. Structure 
  We identified neudesin as a novel secreted protein by analysis of the mouse embryonic cDNA 
database using a computer program for the prediction of the protein localization site in cells 
(PSORT) [1]. Mouse neudesin cDNA encodes a secreted 171-amino acid protein with a putative 
signal sequence at its N-terminus. The amino acid sequence of human neudesin (172 amino acids) is 
highly similar (~91% identity) to that of mouse neudesin. Zebrafish neudesin cDNA encodes 158 
amino acids. Zebrafish neudesin protein is significantly similar (~60% identity) to the mouse 
neudesin protein. As opposed to vertebrates, no neudesin gene is found in invertebrate genomes 
including C. elegans, D. melanogaster, and C. intestinalis. 
  Mouse and human neudesins contain a heme/steroid-binding domain similar to those of PGRMC1 
and cyt-b5, and belong to the MAPR family, a subfamily of the cyt-b5 family, along with PGRMC1 
[60]. The 45-143-amino acid sequence in mouse neudesin is a predicted heme-binding domain, in 
which Tyl-81 and Tyl-87 are the putative binding sites for the heme iron (Fig. 1). Indeed, 
recombinant mouse neudesin was found to bind hemin; however, recombinant mouse mutant 
neudesin, which lacks a crucial part of the heme-binding domain (neudesin∆HBD), does not bind 
hemin [60]. This binding of hemin to neudesin potently encourages the neuroprotective activity of 
the neudesin protein in primary cultured neurons, while neudesin∆HBD exhibited no neuroprotective 
effect. Additionally, in neuroblastoma Neuro2a cells, neudesin-hemin, but not neudesin or hemin 
alone, exhibited neurotrophic and neuroprotective activities. These data indicate that the binding to 
hemin is essential for the biological activity of neudesin.    
 
3.2. Expression 
  In mouse embryos, although neudesin is expressed in several discrete regions, it is expressed most 
abundantly in the developing brain and spinal cord [1]. In the embryonic cerebral cortex, neudesin is 
mostly expressed in the preplate, which mainly consists of postmitotic neural cells, but not in the 
subventricular/ventricular zone, which mainly consist of self-renewing neural precursor cells [61]. In 
contrast to the expression pattern in embryos, neudesin in adult mice is detected in various tissues, 
including the brain, heart, lung, and kidney. In the brain, it is expressed in most neurons but not in 
glial cells, and in the cerebral cortex, hippocampus, thalamus, and hypothalamus [1]. In cultured 
neural precursor cells, it is observed that neudesin expression gradually decreases along with 
differentiation [61]. This temporal expression profile of neudesin in vitro is not consistent with the 
expression in neurons of adult mice in vivo. The reason behind the difference between in vivo and in 
vitro expression remains to be elucidated. Neudesin is also detected in white adipose tissue (WAT) 
but not brown adipose tissue [62]. WAT mainly consists of white adipocytes, which contain large 
lipid droplets. Adipogenesis is the process by which preadipocytes differentiate into mature 
adipocytes [63]. Several transcription factors, which are necessary for adipogenesis, have been 
identified through the study of an immortalized preadipocyte cell lines: 3T3-L1 cells. These factors 
include members of the CCAAT/enhancer-binding protein beta (C/EBPb), C/EBPa, and peroxisome 
proliferator-activated receptor gamma (PPARg). Neudesin is expressed in 3T3-L1 preadipocytes 
before the addition of inducers for adipogenesis; this expression subsequently decreases in the early 
stage of adipogenesis as the expression of C/EBPb increases [62]. In contrast, neudesin expression is 
increased in the late stage of differentiation parallel to the expression of PPARg and C/EBPa [62].   
 
3.3. Signal transduction 
  The signal transduction of neudesin is mainly studied by using cultured neural precursor cells and 
neurons [1, 61]. The activity of neudesin in primary cultured neurons is mediated through the MAPK 
and phosphatidylinositol-3 kinase (PI-3K) pathways [1]. The Gi/Go protein inhibitor pertussis toxin 
(PTX) significantly inhibited the phosphorylation of ERK1/2 by neudesin, which indicates that the 
activity of neudesin may be mediated by the activation of a Gi/Go protein–coupled receptor [1]. 
Neudesin also promoted the phosphorylation of ERK, Akt, and CREB in neural precursor cells, but 
the effect of neudesin was not inhibited by PTX, unlike in the case of the primary neurons [61]. As 
neudesin increased cAMP levels in neural precursor cells, a Gs protein–coupled receptor might be 
involved in the activation of the MAPK, PKA, and PI-3K signal pathways [61]. The signal 
transduction pathway of neudesin appears to change in the course of development. To date, specific 
receptor(s) for neudesin has not yet been reported. Identification of the neudesin receptor(s) may 
provide a clue for the understanding of the unique signal transduction system of neudesin.   
 
3.4. Physiological functions 
  As described in Section 3.2, neudesin is expressed in neural precursor cells, adult neurons, and 
white adipocytes. Recombinant neudesin significantly enhanced survival of primary cultured mouse 
neurons by decreasing apoptosis but exhibited no mitogenic activity in primary cultured mouse 
astrocytes. In contrast, FGF2 had both neurotrophic and mitogenic activities, indicating that the 
activity of neudesin is distinct from that of FGF2 [1]. Recombinant neudesin induced the 
differentiation of neural precursor cells into MAP-2-positive neurons through the PI-3K and PKA 
pathways, and transiently promoted neural cell proliferation in the dividing neural precursor cells 
through the ERK and PKA pathways, but not the PI-3K pathway [61]. Interestingly, Neuro2a cells 
produce endogenous hemin-bound neudesin [60]. Transfection of neudesin siRNA, but not of 
negative control siRNA, significantly reduced cell survival and proliferation in Neuro2a cells, which 
produce neudesin independently, suggesting that endogenous neudesin-hemin is expected to play 
physiological roles in development and maintenance of the nervous system [60]. Neudesin-hemin 
significantly inhibited the late stage of adipogenic inducer-dependent adipogenesis in 3T3-L1 
preadipocytes, but not the early stage [62]. In contrast, transfection of neudesin siRNA enhanced the 
expression of C/EBPa and PPARg and promoted adipogenesis in 3T3-L1 preadipocytes [62]. These 
results and the expression profile during adipogenesis suggest that the decrease in the neudesin level 
in the early stage may be a triggering event for adipogenesis, and neudesin may play potential roles 
in the development of WAT and obesity. Studies of human diseases also provide another approach to 
the physiological functions of neudesin. Expression of progesterone receptor (PR) in estrogen 
receptor (ER)-positive breast tumors correlates with increased probability of tamoxifen 
responsiveness and provides a good prognosis as compared to tumors that express only ER [64]. 
Neudesin protein was shown to be more abundant in ER+/PR+ tumors than ER+/PR- tumors [65].  
An increase in neudesin expression was observed in SV40-transformed human embryonic kidney 
cells immediately following a proliferative crisis [66]. Such information suggests that neudesin may 
be involved in immortalization of tumor cells and/or resistance to carcinogenesis. A recent study has 
shown that the ectopic expression of neudesin promotes invasiveness and tumorigenicity in MCF-7 
breast cancer cells [67]. 
  As summarized in Table 4, the heme-binding protein neudesin is expressed widely in several 
tissues, including the central nervous system and breast tumor cells, and it has a number of functions 
such as cell differentiation and survival. 
 
 
4. Neuferricin (CYB5D2) 
4.1. Structure 
  In 2010, we reported neuferricin as the second secretary member of the MAPR family [2]. In 2011, 
Xie et al. also identified it as the cyt-b5 domain containing 2 (CYB5D2) [68]. Neuferricin was 
identified using a homology-based search with the cyt-b5-like heme/steroid-binding domain of 
neudesin. Phylogenetic analysis has indicated that neuferricin and neudesin are two paralogue genes 
generated from one identical gene of C. elegans by gene duplication during metazoan evolution. The 
human neuferricin has 264 amino acids, and its sequence is conserved from fish to primate. 
Neuferricin contains a signal sequence at its N-terminus, and it was confirmed that this protein is 
effectively secreted into the culture media from High Five cells and Neuro2a cells. The protein 
contains a heme-binding domain at its N-terminal half region, while the other members of the 
MAPR family possess a cyt-b5 domain at C-terminus (Fig. 1). Indeed, endogenous neuferricin is 
secreted in a heme-binding form into the culture medium of Neuro2a cells, although it remains 
unclear how neuferricin binds heme.   
 
4. 2. Expression 
  During the mouse embryonic stage, neuferricin mRNA is primarily expressed in the central 
nervous system, particularly in subventricular zone and ventricular zone of the cerebral cortex and 
olfactory bulb [2]. The expression level of neuferricin gradually increases along with brain 
development. In the postnatal brain, neuferricin mRNA is abundantly expressed, especially in 
pyramidal cells around the CA3 region of Ammon’s horn in the hippocampus. In addition to the 
brain, neuferricin mRNA is widely expressed in several tissues in the postnatal period, including 
those of the heart, adrenal gland, and kidney[2].  
 
4.3. Signal transduction and physiological function 
  So far, neuferricin has been reported to function in two physiological activities: neurogenesis [2] 
and protection from etoposide-induced cytotoxicity [68]. As described in Section 4.2., neuferricin is 
mostly expressed in the brain during the developmental stage and in the hippocampus in the adult 
brain. The suppression of neuferricin by RNA interference in Neuro2a cells promotes cell survival 
and inhibits neurite outgrowths. Furthermore, the neuferricin protein, but not the recombinant form 
of neuferricin lacking the heme-binding domain, significantly suppressed cell survival in Neuro2a 
cells in a concentration-dependent manner. These data suggest that neuferricin is expressed in a 
region of neural precursor cells and promotes neurogenesis by suppressing the self-renewal and 
proliferation of neural stem cells.  Heme binding to neuferricin may be essential for the biological 
activity of neuferricin as well as that of the other member of the MAPR family [60]. In Neuro2a 
cells, siRNA-induced knockdown of neuferricin increased the expression of Bcl-2, a molecule 
involved in apoptosis suppression, but exerted no effect on the expression of p53 and Bax, molecules 
involved in apoptosis promotion. This result indicates that the suppression of cell survival by 
neuferricin appears to be associated with apoptosis due to the inhibition of Bcl-2 expression. In 
contrast to the neurotrophic activity of neudesin being transduced via the MAPK signaling pathway 
[61], neuferricin did not exert any effect on the phosphorylation of ERK1/2 [2]. Additionally, 
neuferricin and neudesin have opposite effects on cell proliferation in Neuro2a cells; neuferricin 
suppresses it [2], while neudesin promotes it [60]. These results suggest that the members of the 
MAPR family have different functions through their distinct intracellular transduction pathways in 
neurotrophic activity. 
  Xie et al. reported the protection activity conferred by neuferricin from etoposide [68]. Just as 
PGRMC1 and Dap1 protect cells from DNA damage-induced toxicity [15, 38], neuferricin enhances 
the survival of HeLa cells suffering from cytotoxicity induced by the topoisomerase II inhibitor 
etoposide. This activity requires the neuferricin N-terminus signal sequence and cyt-b5 domains. 
Since cyt-b5 domain-mediated heme binding is necessary for PGRMC1-mediated resistance, the 
association with heme may contribute to neuferricin-mediated resistance to this cytotoxicity. 
However, neuferricin has no significant effects on etoposide-induced phosphorylation of ataxia 
telangiectasia mutated (ATM) kinase. Neuferricin may protect cells from etoposide-induced 
cytotoxicity independently of ATM-dependent DNA damage response modulation. This idea is also 
supported by the observation that neuferricin does not resist UV-induced apoptosis, which is 
mediated primarily through the ataxia telangiectasia mutated related (ATR) kinase pathway [68, 69]. 
Moreover, neuferricin also does not affect the expression level of Bcl-2 as well as other major 
components of apoptosis in HeLa cells. Taken together, neuferricin may modulate cell survival 
against etoposide-induced cytotoxicity through an unidentified pathway. One possibility is that 
neuferricin may protect heme from chemical-induced damage, as suggested for PGRMC1 [4]. It has 
been demonstrated that PGRMC1 interacts with the P450 protein CYP51A, which is known to 
detoxify toxic compounds [32]. The interaction between neuferricin and CYP51A may contribute to 
neuferricin-mediated resistance to etoposide-induced cytotoxicity.  
  Thus, as shown in Table 5, the heme-binding protein neuferricin is expressed widely in several 
tissues including the central nervous system and is associated with the promotion of neurogenesis 




  As member of the MAPR family, PGRMC1, PGRMC2, neudesin, and neuferricin contain a 
cyt-b5-like heme/steroid-binding domain. MAPR family genes are expressed widely in the central 
nervous system and in several tissues. They have a number of functions, including neurotrophic 
effects, as shown in Table 6. Although their functions are slightly different, all MAPR family 
members, except PGRMC2, appear to share some activities relating to cell differentiation and 
survival. Their bioactivities depend on the binding of heme to their cyt-b5-like heme/steroid-binding 
domains. Thus, the MAPR family members exert some novel, interesting effects as heme-binding 
proteins. Although several published reports have described how progesterone binding to MAPR 
family proteins induces biological responses, their exact function in progesterone signaling remains 
obscure. The knockout of MAPR family genes in mice has also not been reported thus far. Therefore, 
the in vivo functions of these proteins remain unclear. In the future, MAPR family gene knockout 
mice will provide much information on the physiological functions of the MAPR family proteins. 
Elucidation of the MAPR family members' precise functions may provide new insights into the 
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FIGURE LEGENDS  
Fig. (1). Multiple sequence alignment of mouse MAPR family. Cytochrome b5 heme-binding 
(Cyt-b5) domain is indicated by the grey box. Two conserved tyrosine residues, which are important 
for heme binding, are shown in white. The predicted transmembrane domains (PGRMC1 and 
PGRMC2) are single underlined and the predicted signal peptides (neudesin and neuferricin) are 
double underlined.  Reported and speculated phosphorylation sites are shown in grey according to 
UniProtKB. 
 







